Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2021
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2015
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Aptiv Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2013
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Aptiv Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2011
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable